| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Lemborexant (JAN/USAN/INN); Dayvigo (TN) | ||||||
| Product | DAYVIGO (Eisai) | ||||||
| Formula | C22H20F2N4O2 | ||||||
| Exact mass | 410.1554 | ||||||
| Mol weight | 410.4166 | ||||||
| Structure |  | ||||||
| Class | Neuropsychiatric agent DG03225 Orexin receptor antagonist DG03202 Hypnotic Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG02925 CYP3A5 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Hypnotic, Orexin receptor antagonist | ||||||
| Disease | Insomnia [DS:H01609] | ||||||
| Comment | Treatment of insomnia | ||||||
| Target | HCRTR [HSA:3061 3062] [KO:K04238 K04239] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576]; CYP3A5 [HSA:1577] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N05 PSYCHOLEPTICS N05C HYPNOTICS AND SEDATIVES N05CM Other hypnotics and sedatives N05CM21 Lemborexant D11022 Lemborexant (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Sleep Disorder Agents Sleep Promoting Agents Lemborexant D11022 Lemborexant (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 119 Miscellaneous 1190 Miscellaneous D11022 Lemborexant (JAN/USAN/INN) Drug groups [BR:br08330] Neuropsychiatric agent DG03225 Orexin receptor antagonist D11022 Lemborexant DG03202 Hypnotic D11022 Lemborexant Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D11022 Lemborexant DG02925 CYP3A5 substrate D11022 Lemborexant Drug classes [BR:br08332] Neuropsychiatric agent DG03202 Hypnotic D11022 Lemborexant Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Orexin HCRTR D11022 Lemborexant (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11022 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11022 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11022 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11022 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 30 1 C1z C 17.9200 -15.7500 2 C1y C 19.3200 -15.7500 3 C1x C 18.6200 -14.5600 4 C8x C 14.2800 -13.6500 5 C8y C 14.2800 -15.0500 6 C8x C 15.4700 -15.7500 7 C8y C 16.7300 -15.0500 8 C8x C 16.7300 -13.6500 9 C8x C 15.4700 -12.9500 10 C1b C 16.7300 -16.4500 11 O2a O 16.7300 -17.8500 12 C8y C 15.5400 -18.5500 13 C8x C 14.3500 -17.8500 14 N5x N 13.0900 -18.5500 15 C8y C 13.0900 -19.9500 16 N5x N 14.2800 -20.6500 17 C8y C 15.5400 -19.9500 18 C1a C 16.7300 -20.6500 19 C1a C 11.9000 -20.6500 20 X F 13.0900 -15.7500 21 C5a C 20.5100 -16.4500 22 N1b N 20.5100 -17.8500 23 O5a O 21.7000 -15.7500 24 C8y C 21.7224 -18.5500 25 N5x N 21.7224 -19.9498 26 C8x C 22.9349 -20.6498 27 C8y C 24.1473 -19.9498 28 C8x C 24.1473 -18.5500 29 C8x C 22.9349 -17.8500 30 X F 25.3618 -20.6510 BOND 33 1 1 2 1 2 2 3 1 3 3 1 1 4 4 5 2 5 5 6 1 6 6 7 2 7 7 8 1 8 8 9 2 9 4 9 1 10 1 7 1 #Down 11 1 10 1 12 10 11 1 13 11 12 1 14 12 13 2 15 13 14 1 16 14 15 2 17 15 16 1 18 16 17 2 19 12 17 1 20 17 18 1 21 15 19 1 22 5 20 1 23 2 21 1 #Up 24 21 22 1 25 21 23 2 26 22 24 1 27 24 25 2 28 25 26 1 29 26 27 2 30 27 28 1 31 28 29 2 32 24 29 1 33 27 30 1 |